{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. and European Patents and Patent Applications listed in the Supplementary Information section of this Notice to Ridgeback Biotherapeutics, L.P., located in Miami, Florida.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/03/15/2021-05235.html","cfr_references":[],"citation":"86 FR 14331","comment_url":null,"comments_close_on":"2021-03-30","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the National Institute of Allergy and Infectious Diseases' Technology Transfer and Intellectual Property Office on or before March 30, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-05235","effective_on":null,"end_page":14332,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/03/15/2021-05235.xml","html_url":"https://www.federalregister.gov/documents/2021/03/15/2021-05235/prospective-grant-of-an-exclusive-patent-license-development-production-and-commercialization-of","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-05235?publication_date=2021-03-15","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-03-15/2021-05235/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":340,"last_updated":"2026-04-24 16:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-03-15/pdf/2021-05235.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-05235.pdf?1615556720","publication_date":"2021-03-15","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/03/15/2021-05235.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T03:34:19Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":14331,"subtype":null,"title":"Prospective Grant of an Exclusive Patent License: Development, Production, and Commercialization of Ebola Neutralizing Single Monoclonal Antibody for the Treatment of Ebola Virus Disease in Humans","toc_doc":"Development, Production, and Commercialization of Ebola Neutralizing Single Monoclonal Antibody for the Treatment of Ebola Virus Disease in Humans","toc_subject":"Grant of an Exclusive Patent License:\n","topics":[],"type":"Notice","volume":86}